




Searching News Database: Clarity Pharmaceuticals
HSMN NewsFeed - 7 Feb 2022
US FDA "Study May Proceed" Letter for Clarity's Cu-64 SAR-bisPSMA Trial in Prostate Cancer
US FDA "Study May Proceed" Letter for Clarity's Cu-64 SAR-bisPSMA Trial in Prostate Cancer